Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
We have a wide range of fun and festive designs to choose from. Fund life changing research while spreading joy this Christmas!
This Christmas, your gift can bring us closer to a cure for type 1 diabetes – and every pound you give to our Christmas Appeal will be doubled.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
This event is designed for anyone living with type 1 diabetes who would like to learn more about managing their wellbeing across a variety of contexts.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > About JDRF & Our Impact > Our research > Research projects > Improving screening tests for type 1 diabetes
Screening the UK population for type 1 diabetes is vital for detecting the condition early and reducing the number of people diagnosed in crisis in diabetic ketoacidosis. We are funding a screening programme in the UK called The ELSA Study, in which researchers are testing 20,000 children in the UK for type 1 diabetes. Improving the screening test used in the ELSA Study will increase its chances of success and help accelerate the UK towards a routine national screening programme for type 1.
Currently, the ELSA study involves three rounds of blood tests to pin-point which markers of type 1 (known as antibodies) are present in each child’s blood. Each test is sent to a lab to be processed, leaving families with an anxious wait for results.
To streamline the screening process, Alex will develop a lateral flow test for type 1, similar to the ones commonly used to test for COVID. The test will show all four different antibodies that are markers of type 1 diabetes risk.
Once Alex finishes developing her screening test, families can use it at home at their convenience to get immediate results on their risk of type 1. This will give instant reassurance to the 99% of individuals who will receive a negative result. The home test kits will also allow DNA collection which can be posted back to the laboratories to check a person’s genetic risk of type 1.
There are advantages and disadvantages to both genetic and antibody tests, so testing for both covers more bases. The antibody tests show whether someone is currently in the early stages of developing type 1, but they are a snapshot in time. Whereas the genes we have don’t change. If you have certain genes, you are more likely to develop type 1, but you may never actually develop it. By combining the results of both tests, healthcare professionals can make a more informed judgement about a person’s risk of developing type 1.
An effective screening test is key to an effective screening programme for type 1 diabetes, which could completely change how we manage type 1 globally.
In the short-term, Alex’s faster, more convenient screening test will encourage more families to get their children screened for type 1. Her test will allow screening programmes to run more efficiently and be more successful. This will hopefully lead to lower numbers of children being diagnosed in the dangerous state of diabetic ketoacidosis due to the increased awareness and education that screening brings.
The longer-term benefit of an effective screening programme will be offering prevention studies to children in the earliest stages of type 1 diabetes. Some medicines (like teplizumab) can safely delay children getting type 1 diabetes by over three years. With teplizumab now approved for use in the US, it is more important than ever to establish a population screening programme in the UK so that we are ready when the drug is approved here.
We are funding the ELSA Study, which is the screening project for type 1 diabetes that Alex is developing her improved antibody test for. By funding both projects, we are ensuring the screening study achieves the best possible results.
We also fund Professor Richard Oram’s work to develop a risk score calculator for type 1. Healthcare professionals can input a patient’s age, genes and antibodies to determine their risk of developing type 1 in the next year, three years and five years.
This award will help to fund the next generation of immunotherapy research, enabling more efficient clinical trials, in more locations, so that promising treatments can reach people sooner.
This project aims to overcome two major roadblocks to developing and licensing immunotherapies for people newly diagnosed with type 1 diabetes.
Dr Bewick is exploring ways to improve the health, performance and number of beta cells in the body, so that people with type 1 can be less reliant on insulin pumps and injections – or even, one day, live without them completely.
This project is looking at a new way to turn stem cells into beta cells in the lab, to better understand what conditions make this process happen efficiently.